UMR1078

UMR 1078
Genetics, functional genomics
and biotechnology

Publications de Microbiota

Publications (depuis 4 ans) en lien avec la thématique de recherche

  •  Le Gall F, Le Berre R, Rosec S, Hardy J, Gouriou S, Boisramé-Gastrin S, Vallet S, Rault G, Payan C, Héry-Arnaud G. Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis. BMC Microbiol. 2013 Jun 13:143
  •  Mounier J, Gouëllo A, Keravec M, Le Gal S, Pacini G, Debaets S, Nevez G, Rault G, Barbier G, Héry-Arnaud G. Use of denaturing high-performance liquid chromatography (DHPLC) technique for the characterization of the bacterial and fungal airway microbiota of cystic fibrosis patients. J Microbiol. 2014 Apr;52(4):307-14
  •  Alexandre Y, Le Berre R, Barbier G, Le Blay G. Screening of Lactobacillus spp. for the prevention of Pseudomonas aeruginosa pulmonary infections. BMC Microbiology. 2014 Apr 27;14:107.
  • Alexandre Y, Le Blay G, Boisrame-Gastrin S, Le Gall F, Héry-Arnaud G, Gouriou S, Vallet S, Le Berre R. Probiotics: A new way to fight bacterial pulmonary infections ? Médecine et Maladies Infectieuses. 2014 44(1):9-17.
  • Fangous MS, Mougari F, Gouriou S, Calvez E, Raskine L, Cambau E, Payan C, Héry-Arnaud G. A classification algorithm for subspecies identification within the Mycobacterium abscessus species, based on Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. J Clin Microbiol. 2014 Sep;52(9):3362-9
  • Bernarde C, Keravec M, Mounier J, Gouriou S, Rault G, Férec C, Barbier G, Héry-Arnaud G. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation. PLoS ONE. 2015 Apr 8;10(4):e0124124.
  • Rivas Caldas R, Le Gall F, Revert K, Rault G, Virmaux M, Gouriou S, Héry-Arnaud G, Barbier G, Boisramé S. Pseudomonas aeruginosa and Periodontal Pathogens in the Oral Cavity and Lungs of Cystic Fibrosis Patients: a Case-Control Study. J Clin Microbiol. 2015 Jun;53(6):1898-907.
  • Keravec M, Mounier J, Prestat E, Vallet S, Jansson JK, Burgaud G, Rosec S, Gouriou S, Rault G, Coton E, Barbier G, Héry-Arnaud G. Insights into the respiratory tract microbiota of patients with cystic fibrosis during early Pseudomonas aeruginosa colonization. Springerplus. 2015 Aug 9;4:405.
  • Rivas-Caldas R, Boisramé S. Upper aero-digestive contamination by Pseudomonas aeruginosa and implications in cystic fibrosis. Journal of Cystic Fibrosis. 2015 14(1):6-15.
  • Meijer L, Nelson D, Riazanski V, Gabdoulkhakova AG, Héry-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothee G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel R, Mottier D, Rault G. Modulating innate and adaptative immunity by (R)- roscovitine: potential therapeutic opportunity in cystic fibrosis. J Innate Immunity 2016;8(4):330-49.
  • Billard L, Le Berre R, Pilorgé L, Payan C, Héry-Arnaud G, Vallet S. Viruses in cystic fibrosis patients’ airways. Critical Reviews in Microbiology. 2017 Mar 24:1-19.
  • Héry-Arnaud G, Nowak E, Caillon J, David V, Dirou A, Revert K, Munck MR, Frachon I, Haloun A, Horeau-Langlard D, Le Bihan J, Danner-Boucher I, Ramel S, Pelletier MP, Rosec S, Gouriou S, Poulhazan E, Payan C, Férec C, Rault G, Le Gal G, Le Berre R. Evaluation of quantitative PCR for early diagnosis of Pseudomonas aeruginosa infection in cystic fibrosis: a prospective cohort study. Clin Microbiol Infect. 2017 May 27. pii: S1198-743X(17)30277-X.

 

Marque Bretagne